US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Bulletin from the Annual General Meeting of Redsense Medical AB (publ) on May 20, 2026

Redsense Medical AB (publ) (“Redsense Medical” or the “Company”) held its Annual General Meeting (the “AGM”) on Wednesday May 20, 2026, in Halmstad, at which the following main resolutions were adopted. All resolutions were passed with the required majority. For detailed information regarding the content of the resolutions, please refer to the notice of the AGM and the complete proposals available on the Company's website, www.redsensemedical.com. Appropriation of the result The AGM resolved, in accordance with the Board of Directors' amended proposal, that the distributable funds

Interim Report Q1 – January – March, 2026 Redsense Medical AB (publ.)

January – March 2026 • Net sales amounted to kSEK 6,402 (4,776). • Operating result, EBIT amounted to kSEK 1,077 (-3,152). • Excl. Exchange rate differences kSEK 657 (-1,192). • Result after tax amounted to kSEK 1,119 (-3,152). • Earnings per share were SEK 0,07 (-0,19). • Exchange rate differences kSEK 420 (-1,960). (Other operating income/loss) Significant Events during the period • On February 26, Redsense announced first Clamp System sale to UK clinic. • On March 10, Redsense announces that the Company’s Nomination Committee proposes that Michael A

NOTICE TO THE ANNUAL GENERAL MEETING OF REDSENSE MEDICAL AB (PUBL)

Redsense Medical AB (publ) will hold its Annual General Meeting on Wednesday, May 20, 2026 at 16.30 at Profilhotels Halmstad Plaza, Anna Lindhs Plats, 302 66 Halmstad. Registration takes place from 16.00. Before the Annual General Meeting, light refreshments will be served and the company's products will be displayed. RIGHT TO PARTICIPATE AND NOTIFICATION TO THE COMPANY Anyone wishing to attend the meeting must: i. be registered as a shareholder in the share register kept by Euroclear Sweden AB on Monday, May 11, 2026; andii. notify the company of their intention to participate

Michael A Kraus proposed to the board of Redsense Medical AB

Halmstad, Sweden, March 10, 2026 – Redsense Medical AB (publ) (“Redsense'' or “the Company”) announces that the Company’s Nomination Committee proposes that Michael A Kraus be elected as a new board member at the annual general meeting on May 20, 2026. Michael A Kraus is a nephrologist with 35 years of experience. He trained at the University of Iowa and later held faculty positions there as well as at Indiana University. He served at Indiana University for 25 years, rising to the rank of Clinical Professor and Clinical Chief. Michael later joined the dialysis industry as Associate Chief

Redsense Medical announces first Clamp System sale to UK clinic

Halmstad, Sweden, February 26, 2026 – Redsense Medical AB (publ) (“Redsense'' or “the Company”) announces that the Company’s UK distributor has received its first order for the Redsense Clamp System for delivery to an end customer in the UK. The order covers two Clamp Systems purchased together with Redsense Alarm units for immediate implementation at a UK clinic. The distributor aims to build on this initial implementation through ongoing discussions regarding broader adoption, with Redsense supporting the process. “This initial order is an important milestone and the first Clamp

Redsense releases Aktiespararna CEO interview following Q4 2025 report

Halmstad, Sweden, February 19, 2026 – Redsense Medical AB (publ) (“Redsense'' or “the Company”) announces that a video interview with CEO Sebastien Bollue has been published by Aktiespararna. In the interview, Sebastien Bollue comments on the recently released Q4 2025 report, reflects on the past year, and provides priorities for 2026. The interview is available on the Aktiespararna website:  https://www.aktiespararna.se/analyser/vd-intervju-redsense-medical It is also accessible via the following link: https://www.youtube.com/watch?v=YEQi1QQTYg8

Interim Report Q4 – October – December, 2025 Redsense Medical AB (publ.)

October – December 2025 · Net sales amounted to kSEK 6,035 (12,687). · Operating loss, EBIT amounted to kSEK -1,952 (5,525). · Excl. Exchange rate differences kSEK -1,549 (3,754) · Result after tax amounted to kSEK -1,844 (5,629). · Earnings per share were SEK -0,11 (0,34). · Exchange rate differences kSEK -403 (1,771).(Other operating income/loss) January – December 2025 · Net sales amounted to kSEK 24,023 (28,176). · Operating loss, EBIT amounted to kSEK -7,366 (210). · Excl. Exchange rate differences kSEK -3,718 (-1,753) · Result after tax amounted

Redsense releases BioStock CEO interview following Q3 2025 report

Halmstad, Sweden, November 19, 2025 – Redsense Medical AB (publ) (“Redsense'' or “the Company”) announces that a video interview with CEO Sebastien Bollue has been published by BioStock. In the interview, Sebastien Bollue comments on the recently released Q3 2025 report, reflects on his tenure as CEO, and provides a short outlook. The interview is available at the following link: https://biostock.se/2025/11/redsense-medical-vi-har-ett-valdigt-starkt-fokus-framat/ It is also accessible via the BioStock website: www.biostock.se

Interim Report Q3 – July – September, 2025 Redsense Medical AB (publ.)

July – September 2025 · Net sales amounted to kSEK 6,935 (5,030). · Operating loss, EBIT amounted to kSEK -428 (-3,272). · Excl. Exchange rate differences kSEK -226 (-1,914) · Result after tax amounted to kSEK -345 (-3,271). · Earnings per share were SEK -0,21 (-1,99). · Exchange rate differences kSEK -202 (-1,358). (Other operating income/loss) January – September 2025 · Net sales amounted to kSEK 17,988 (15,490). · Operating loss, EBIT amounted to kSEK -5,414 (-5,316). · Excl. Exchange rate differences kSEK -2,169 (-3,422) · Result after tax

Redsense initiates pilot study with a global leading dialysis provider in Germany

Halmstad, Sweden, November 18, 2025 – Redsense Medical AB (publ) (“Redsense'' or “the Company”) today announces that the Company will conduct a pilot study in collaboration with a global leading dialysis care provider at a partner clinic in Berlin, Germany, starting in December 2025. The study will evaluate the Redsense Blood Leakage Alarm system in a real-world clinical environment and generate updated data on usability, risk reduction of blood leakage and workflow integration. “Collaborating with one of the leading clinical operators in the European dialysis market marks another

Redsense Medical initiates sales activities in Australia following TGA approval of Redsense Clamp

Halmstad, Sweden, November 7, 2025 – Redsense Medical AB (publ) (“Redsense” or “the Company”) announces that the Redsense Clamp System has been granted regulatory approval from the Australian Therapeutic Goods Administration (TGA), allowing the product to be sold and marketed in Australia. With the registration now in place, Redsense and its local distribution partner, Regional Health Care Group (RHCG), are initiating preparations for sales, training, and education activities in the market. RHCG was appointed as Redsense’s distributor for Australia in anticipation of the Clamp, and has

Nomination committee appointed for the 2026 Annual General Meeting in Redsense Medical AB

A nomination committee has been established ahead of the 2026 annual general meeting in Redsense Medical AB (publ). The nomination committee, which has been appointed in accordance with the principles adopted by the annual general meeting May 28, 2025, consists of: Johannes Köpple, appointed by ShapeQ GmbH Susanne Olauson, appointed by Seventh Sense Adventures Holding AB Oscar Bergman, appointed by Swedbank Robur Fonder Susanne Olauson, the chairman of the board is convening The nomination committee's task is to submit proposals to the annual general meeting regarding;

Interim Report Q2 – April – June, 2025 Redsense Medical AB (publ.)

April – June 2025 · Net sales amounted to kSEK 6,276 (8,749). · Operating loss, EBIT amounted to kSEK -1,833 (613). · Excl. Exchange rate differences kSEK -750 (-39) · Result after tax amounted to kSEK -1,830 (625). · Earnings per share were SEK -1,11 (0.04). · Other operating income/loss kSEK -1,083 (652). Significant Events during the period · On April 7, Redsense updates on tariffs and Clamp. · On April 24, Redsense held an Extraordinary General Meeting and announced that CFO Peter Larsson would enter as a temporary member of the Board of Directors. ·

Redsense Clamp CE marked and introduced across key markets

Redsense Medical is pleased to announce that the clamp is CE marked and has been introduced in the UK, Canadian, and German markets. We have been working closely with our distribution partners and dialysis providers, with the first demonstrations performed and pilot study discussions started. “Being able to place the CE mark on our device was a defining moment, but the real progress is happening now as we work alongside our partners and clinical contacts to ensure a smooth introduction,” said Sebastien Bollue, CEO at Redsense Medical. “We’re also developing optimised visuals, marketing

Redsense Medical receives preemptive order ahead of pending tariff increase

Redsense Medical has received a preemptive order from a US distribution partner as a proactive measure in anticipation of a pending potential tariff increase. The order, originally scheduled for fulfillment in September, represents an estimated quarters worth of product with that distribution partner, and has been advanced to July as part of a strategic effort to mitigate potential cost impacts associated with upcoming trade changes. The company continues to monitor trade developments closely and remains committed to supporting its partners through flexible and responsive supply chain

Bulletin from the Annual General Meeting of Redsense Medical AB (publ) on May 28, 2025

Redsense Medical AB (publ) (“Redsense Medical” or the “Company”) held its Annual General Meeting (the “AGM”) on Wednesday May 28, 2025, in Halmstad, at which the following main resolutions were adopted. All resolutions were passed with the required majority. For detailed information regarding the content of the resolutions, please refer to the notice of the AGM and the complete proposals available on the Company's website, www.redsensemedical.com. Appropriation of the result The AGM resolved, in accordance with the Board of Directors' amended proposal, that the distributable funds

Interim Report Q1 – January – March, 2025 Redsense Medical AB (publ.)

January – March 2025 · Net sales amounted to kSEK 4,776 (1,711). · Operating loss, EBIT amounted to kSEK -3,152 (-2,656). · Result after tax amounted to kSEK -3,152 (-2,640). · Earnings per share were SEK -0,19 (-0,19). · Other operating income/loss kSEK -1,960 (952). Significant Events during the period · On January 21, Redsense announced the completion of the Clamp usability testing phase. · On January 24, Redsense announced an indicative strong closing of Q4 2024. · On January 31, Redsense announced the passing of Board Member Malin Almgren. · On

Amendment: NOTICE TO THE ANNUAL GENERAL MEETING OF REDSENSE MEDICAL AB (PUBL)

The notice of the general meeting published on April 28th contained an incorrect figure in the appropriation of profits. The free share premium reserve was not included, which has now been corrected to 47,318,347 SEK below. ____________ Redsense Medical AB (publ) will hold its Annual General Meeting on Wednesday, May 28, 2025 at 16.30 at Profilhotels Halmstad Plaza, Anna Lindhs Plats, 302 66 Halmstad. Registration takes place from 16.00. Before the Annual General Meeting, light refreshments will be served and the company's products will be displayed. RIGHT TO PARTICIPATE AND

Changed date for publication of interim report Q1 2025

Redsense Medical announces that the publication of the interim report for the first quarter of 2025 will take place on 28 May 2025, instead of the previously communicated date of 14 May 2025. Historically, the company has published its Q1 report on the same day as its Annual General Meeting to ensure consistent and transparant information disclosure. As the 2025 Annual General Meeting has been rescheduled to 28 May, the publication date of the Q1 report is being adjusted accordingly. The interim report for the first quarter of 2025 will be published on 28 May 2025 at 08:00.

Clamp nears market lauch as summative evaluation review completed

Redsense Medical announces that the summative evaluation review for the Clamp has been successfully completed by the independent test house. This marks a key milestone in the product’s journey to market, confirming its compliance with the highest standards of performance, safety, and reliability. With the evaluation phase now concluded, the Clamp is in its final pre-launch stage. Remaining steps now include the finalization and release of internal design documentation, instructions for use, labelling, and completing the certificate of conformity, including CE marking. The Clamp will be

NOTICE TO THE ANNUAL GENERAL MEETING OF REDSENSE MEDICAL AB (PUBL)

The Board of Directors of Redsense Medical AB (publ) has decided to convene an Annual General Meeting on Wednesday May 28, 2025. Further details regarding the proposal for the Annual General Meeting are set out in the notice, which is presented in its entirety below. The notice will be published in Post- och Inrikes Tidningar and on the company's website in the coming days. Redsense Medical AB (publ) will hold its Annual General Meeting on Wednesday, May 28, 2025 at 16.30 at Profilhotels Halmstad Plaza, Anna Lindhs Plats, 302 66 Halmstad. Registration takes place from 16.00. Before

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe